JP7811085B2 - セピアプテリンを含む医薬組成物及びその使用 - Google Patents

セピアプテリンを含む医薬組成物及びその使用

Info

Publication number
JP7811085B2
JP7811085B2 JP2020512443A JP2020512443A JP7811085B2 JP 7811085 B2 JP7811085 B2 JP 7811085B2 JP 2020512443 A JP2020512443 A JP 2020512443A JP 2020512443 A JP2020512443 A JP 2020512443A JP 7811085 B2 JP7811085 B2 JP 7811085B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
sepiapterin
less
salt
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020512443A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020532535A (ja
JP2020532535A5 (https=
Inventor
ダニエル， イー． レヴィー，
Original Assignee
ピーティーシー セラピューティクス エムピー，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピーティーシー セラピューティクス エムピー，インコーポレイテッド filed Critical ピーティーシー セラピューティクス エムピー，インコーポレイテッド
Publication of JP2020532535A publication Critical patent/JP2020532535A/ja
Publication of JP2020532535A5 publication Critical patent/JP2020532535A5/ja
Priority to JP2023088749A priority Critical patent/JP2023116556A/ja
Application granted granted Critical
Publication of JP7811085B2 publication Critical patent/JP7811085B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2020512443A 2017-09-01 2018-09-04 セピアプテリンを含む医薬組成物及びその使用 Active JP7811085B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023088749A JP2023116556A (ja) 2017-09-01 2023-05-30 セピアプテリンを含む医薬組成物及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762553603P 2017-09-01 2017-09-01
US62/553,603 2017-09-01
US201862678069P 2018-05-30 2018-05-30
US62/678,069 2018-05-30
PCT/US2018/049359 WO2019046849A1 (en) 2017-09-01 2018-09-04 PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023088749A Division JP2023116556A (ja) 2017-09-01 2023-05-30 セピアプテリンを含む医薬組成物及びその使用

Publications (3)

Publication Number Publication Date
JP2020532535A JP2020532535A (ja) 2020-11-12
JP2020532535A5 JP2020532535A5 (https=) 2021-10-14
JP7811085B2 true JP7811085B2 (ja) 2026-02-04

Family

ID=65526057

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020512443A Active JP7811085B2 (ja) 2017-09-01 2018-09-04 セピアプテリンを含む医薬組成物及びその使用
JP2023088749A Pending JP2023116556A (ja) 2017-09-01 2023-05-30 セピアプテリンを含む医薬組成物及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023088749A Pending JP2023116556A (ja) 2017-09-01 2023-05-30 セピアプテリンを含む医薬組成物及びその使用

Country Status (7)

Country Link
US (3) US11752154B2 (https=)
EP (1) EP3675863A4 (https=)
JP (2) JP7811085B2 (https=)
CN (1) CN111491635A (https=)
CA (1) CA3073957A1 (https=)
MX (1) MX2020002271A (https=)
WO (1) WO2019046849A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2562176B1 (en) 2010-04-22 2018-08-15 Nihon University Medicinal agent and beverage/food for preventing cerebral dysfunction and improving same
MA46972A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Forme polymorphe de sépiaptérine
MA46973A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Polymorphes de sépiaptérine et leurs sels
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
FI3801536T3 (fi) 2018-05-30 2024-08-29 Ptc Therapeutics Mp Inc Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi
EP3801534B1 (en) 2018-05-30 2026-02-18 PTC Therapeutics MP, Inc. Treatment of phenylketonuria with sepiapterin
AU2019277372B2 (en) 2018-05-30 2024-12-19 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin
IL290321B1 (en) 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment
IL291565B1 (en) * 2019-09-25 2026-04-01 Ptc Therapeutics Inc Method for treating phenylalanine irregularity
EP4093405A1 (en) 2020-01-24 2022-11-30 PTC Therapeutics MP, Inc. Methods for treating parkinson's disease with sepiapterin
WO2021168206A1 (en) * 2020-02-19 2021-08-26 Musc Foundation For Research Development L-sepiapterin and methods of use for treating diseases and disorders
WO2022173823A1 (en) 2021-02-09 2022-08-18 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin
IL305037A (en) 2021-02-09 2023-10-01 Ptc Therapeutics Mp Inc Methods of treating glioblastomas with spiafatrin
PE20241579A1 (es) 2021-09-29 2024-08-01 Ptc Therapeutics Inc Composicion farmaceutica de sepiapterina

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004521151A (ja) 2001-07-07 2004-07-15 アストラゼネカ アクチボラグ フルベストラントを含む製剤
JP2005511494A (ja) 2001-08-07 2005-04-28 インデナ エッセ ピ ア 頭皮疾患の治療のための経口組成物
JP2008520574A (ja) 2004-11-17 2008-06-19 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリンの安定性錠剤処方物
WO2011132435A1 (ja) 2010-04-22 2011-10-27 学校法人日本大学 脳機能障害予防・改善用の薬剤及び飲食物
JP2011530540A (ja) 2008-08-12 2011-12-22 オルファ スイス ゲーエムベーハー テトラヒドロビオプテリンを含有する医薬剤形
JP2012533633A (ja) 2009-07-20 2012-12-27 ベテゲン・エルエルシー 経口投与のための安定な薬学的オメプラゾール製剤
WO2016089766A1 (en) 2014-12-02 2016-06-09 Minerva Neurosciences, Inc. Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
WO2017075256A1 (en) 2015-10-27 2017-05-04 Insys Development Company, Inc. Liquid buprenorphine formulations
JP2017515821A (ja) 2014-05-12 2017-06-15 アルファ ワッセルマン ソシエタ ペル アチオニＡｌｆａ Ｗａｓｓｅｒｍａｎｎ Ｓ．Ｐ．Ａ． リファキシミンの新規溶媒和物結晶形、生成物、組成物及びそれらの使用
JP2017114776A (ja) 2015-12-21 2017-06-29 備前化成株式会社 高度不飽和脂肪酸含有組成物及び該組成物を含有する食品
JP2019535836A (ja) 2016-11-29 2019-12-12 センサ ファーマシューティカルズ インコーポレイテッドＣｅｎｓａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． セピプテリン及びその塩の多形

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
EP0722731B1 (en) 1994-08-05 2002-06-05 Suntory Limited Remedy for spinocerebellar degeneration
JP2002515965A (ja) 1995-08-18 2002-05-28 ダブリュー． ランドリ，ドナルド 抗体触媒反応の調節による有機化合物の検出
US8188043B2 (en) * 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
JP2007509909A (ja) 2003-10-31 2007-04-19 アルタナ　ファルマ　アクチエンゲゼルシャフト 呼吸器疾患の治療のためのｂｈ４の使用
JP5184783B2 (ja) 2003-11-17 2013-04-17 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリン、及びテトラヒドロビオプテリン類似体の製造方法
EP1687308B1 (en) 2003-11-17 2019-06-12 Merck & Cie Process for preparating (6R)-L-erythrotetrahydrobiopterin hydrochloride crystalline form B from other crystalline forms
PL1708690T3 (pl) 2003-11-17 2017-01-31 Biomarin Pharmaceutical Inc. Leczenie fenyloketonurii za pomocą BH4
JP2008523090A (ja) 2004-12-08 2008-07-03 バイオマリン ファーマシューティカル インコーポレイテッド 新生児肺高血圧症の治療のための方法および組成物
BRPI0609421B1 (pt) 2005-04-28 2021-06-01 Shiratori Pharmaceutical Co., Ltd. Processos para produção de um composto 1,1-bis-alquil sulfonila, para produção de um composto aldeído, e para produção de um derivado de hidrazona
US20080075666A1 (en) * 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
LT2545939T (lt) 2007-04-11 2021-03-10 Biomarin Pharmaceutical Inc. Tetrahidrobiopterinas, skirtas gydyti ligas, susijusias supadidėjusiu fenilalanino kiekiu
EA017064B1 (ru) 2008-03-10 2012-09-28 Такеда Фармасьютикал Компани Лимитед Кристаллическое производное бензимидазола
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
CA2771432A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
CN103458900A (zh) 2011-03-01 2013-12-18 鲁必康研究私人有限公司 四氢生物蝶呤的稳定组合物
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
CN104736539B (zh) * 2012-05-07 2017-09-01 白鸟制药株式会社 墨蝶呤和四氢乳酰蝶呤的制造法
ES2586945T3 (es) * 2014-03-31 2016-10-19 Vasopharm Gmbh Composiciones farmacéuticas sólidas que comprenden derivados de biopterina y usos de dichas composiciones
EP3468534A4 (en) 2016-06-13 2020-02-05 Meharry Medical College MODULATION OF THE NITROGEN OXIDE SYNTHASE SIGNAL PATH FOR ORAL HEALTH
WO2018019931A1 (en) * 2016-07-29 2018-02-01 Dipharma S.A. Pharmaceutical composition kit comprising sapropterin dihydrochloride
MA46972A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Forme polymorphe de sépiaptérine
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
AU2019277372B2 (en) 2018-05-30 2024-12-19 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin
FI3801536T3 (fi) 2018-05-30 2024-08-29 Ptc Therapeutics Mp Inc Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi
EP3801534B1 (en) 2018-05-30 2026-02-18 PTC Therapeutics MP, Inc. Treatment of phenylketonuria with sepiapterin
IL290321B1 (en) 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment
IL291565B1 (en) 2019-09-25 2026-04-01 Ptc Therapeutics Inc Method for treating phenylalanine irregularity

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004521151A (ja) 2001-07-07 2004-07-15 アストラゼネカ アクチボラグ フルベストラントを含む製剤
JP2005511494A (ja) 2001-08-07 2005-04-28 インデナ エッセ ピ ア 頭皮疾患の治療のための経口組成物
JP2008520574A (ja) 2004-11-17 2008-06-19 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリンの安定性錠剤処方物
JP2011530540A (ja) 2008-08-12 2011-12-22 オルファ スイス ゲーエムベーハー テトラヒドロビオプテリンを含有する医薬剤形
JP2012533633A (ja) 2009-07-20 2012-12-27 ベテゲン・エルエルシー 経口投与のための安定な薬学的オメプラゾール製剤
WO2011132435A1 (ja) 2010-04-22 2011-10-27 学校法人日本大学 脳機能障害予防・改善用の薬剤及び飲食物
JP2017515821A (ja) 2014-05-12 2017-06-15 アルファ ワッセルマン ソシエタ ペル アチオニＡｌｆａ Ｗａｓｓｅｒｍａｎｎ Ｓ．Ｐ．Ａ． リファキシミンの新規溶媒和物結晶形、生成物、組成物及びそれらの使用
WO2016089766A1 (en) 2014-12-02 2016-06-09 Minerva Neurosciences, Inc. Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
WO2017075256A1 (en) 2015-10-27 2017-05-04 Insys Development Company, Inc. Liquid buprenorphine formulations
JP2017114776A (ja) 2015-12-21 2017-06-29 備前化成株式会社 高度不飽和脂肪酸含有組成物及び該組成物を含有する食品
JP2019535836A (ja) 2016-11-29 2019-12-12 センサ ファーマシューティカルズ インコーポレイテッドＣｅｎｓａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． セピプテリン及びその塩の多形

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Clin. Chim. Acta. 93(2):251-62 (1979)

Also Published As

Publication number Publication date
CA3073957A1 (en) 2019-03-07
JP2020532535A (ja) 2020-11-12
CN111491635A (zh) 2020-08-04
US11752154B2 (en) 2023-09-12
BR112020003865A2 (pt) 2020-09-08
US20250195526A1 (en) 2025-06-19
US20240100054A1 (en) 2024-03-28
MX2020002271A (es) 2020-10-05
JP2023116556A (ja) 2023-08-22
EP3675863A4 (en) 2021-01-27
EP3675863A1 (en) 2020-07-08
US12213982B2 (en) 2025-02-04
BR112020003865A8 (pt) 2022-08-16
US20200061070A1 (en) 2020-02-27
WO2019046849A1 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
JP7811085B2 (ja) セピアプテリンを含む医薬組成物及びその使用
JP7778477B2 (ja) セピアプテリンの薬学的に許容される塩
JP7502197B2 (ja) セピアプテリン血漿曝露を増加させるための方法
JP7547215B2 (ja) テトラヒドロビオプテリン血漿曝露を増加させるための組成物及び方法
JP7855033B2 (ja) テトラヒドロビオプテリン血漿曝露を増加させるための組成物及び方法
HK40087700A (zh) 墨蝶呤的药学上可接受的盐
BR112020003865B1 (pt) Composições farmacêuticas compreendendo sepiapterina e usos das mesmas
EA042976B1 (ru) Фармацевтически приемлемые соли сепиаптерина
EA049074B1 (ru) Фармацевтически приемлемые соли сепиаптерина

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210901

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220727

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221207

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230531

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230619

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250924

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260123

R150 Certificate of patent or registration of utility model

Ref document number: 7811085

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150